TABLE 1.
Clinical Characteristics of patients in the lCI Cohort according to γδ t Cell Subgroup (n = 240)
| Clinical Variable | LR n = 119 (%) | HR n = 121 (%) | P Value |
|---|---|---|---|
|
| |||
| Sex | 0.886 | ||
| Male | 104 (87.4) | 105 (86.8) | |
| Female | 15 (12.6) | 16 (13.2) | |
| Age, years | 0.999 | ||
| ≤50 | 60 (50.4) | 61 (50.4) | |
| >50 | 59 (49.6) | 60 (49.6) | |
| HBV virus status | 0.036 | ||
| None | 17 (14.2) | 7 (5.8) | |
| Chronic carrier | 83 (69.7) | 75 (62.0) | |
| Active viral replication | 19 (15.9) | 39 (32.2) | |
| AFP | 0.020 | ||
| Normal | 72 (60.5) | 55 (45) | |
| Elevated | 47 (39.5) | 66 (55) | |
| CEA | 0.305 | ||
| Normal | 63 (52.9) | 72 (59.5) | |
| Elevated | 56 (47.1) | 49 (40.5) | |
| CA 19– 9 | 0.714 | ||
| Normal | 74 (62.2) | 78 (64.5) | |
| Elevated | 45 (37.8) | 43 (35.5) | |
| BCLC stage | 0.084 | ||
| 0 | 7 (6.66) | 12 (10.3) | |
| A | 81 (76.4) | 71 (60.7) | |
| B | 7 (6.66) | 16 (13.7) | |
| C | 11 (10.4) | 18 (15.4) | |
| TNM staging | 0.005 | ||
| I | 58 (54.21) | 39 (32.50) | |
| II | 31 (28.97) | 48 (40.00) | |
| III | 18 (16.82) | 33 (27.50) | |
| Okuda staging | 0.414 | ||
| 0 | 92 (87.6) | 99 (83.8) | |
| 1 | 13 (12.4) | 19 (16.2) | |
| CLIP staging | 0.222 | ||
| Early (0–2) | 101 (84.9) | 109 (90.1) | |
| Late (3–5) | 18 (15.1) | 12 (9.9) | |
| Multinodular | 0.047 | ||
| No | 100 (84.0) | 89 (73.5) | |
| Yes | 19 (16.0) | 32 (26.5) | |
| Tumor size, cm | 0.062 | ||
| ≤3 | 43 (36.1) | 30 (25.0) | |
| >3 | 76 (63.9) | 90 (75.0) | |
| Microvascular invasion | 0.021 | ||
| No | 58 (63.0) | 47 (46.5) | |
| Yes | 34 (37.0) | 54 (53.5) | |
| Cirrhosis | 0.101 | ||
| No | 14 (11.8) | 7 (5.8) | |
| Yes | 105 (88.2) | 114 (94.2) | |
Bold indicates significant value (P < 0.05).
Abbreviations: AVR- CC, active viral replication chronic carrier; CC, chronic carrier.